表紙
市場調査レポート

疼痛管理薬および疼痛管理装置の世界市場

The Global Market for Pain Management Drugs and Devices

発行 BCC Research 商品コード 96391
出版日 ページ情報 英文 243 pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
疼痛管理薬および疼痛管理装置の世界市場 The Global Market for Pain Management Drugs and Devices
出版日: 2015年09月30日 ページ情報: 英文 243 pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の疼痛管理薬・装置市場は、2014年の366億米ドルから、2015年に約378億米ドル、そして2020年に443億米ドルへ拡大すると予測され、2015年から2020年のCAGRは3.2%が見込まれています。

当レポートでは、疼痛管理分野における医薬品および装置市場について分析し、業界動向、疼痛治療薬、市場規模、市場に参入する主要企業のプロファイルを織り交ぜ、お届けします。

第1章 イントロダクション

第2章 サマリー

第3章 業界概要

  • 疼痛および疼痛治療の歴史
  • 疼痛の診断方法
  • 疼痛の治療方法
  • 人口統計および人口高齢化
  • 疼痛管理の必要性
  • 片頭痛管理
  • HIV/HIDS関連の疼痛
  • 術後疼痛
  • 小児の疼痛

第4章 業界動向

  • 概要
  • 過少治療の問題
  • 疼痛の治療と専門家が直面する課題
  • 処方薬モニタリングプログラム
  • ケアへのアクセス
  • オピオイド誘発性便秘の予防およびコンプライアンス低下
  • マネージドケア疼痛管理の問題
  • 疼痛治療のFDA認可要件
  • 疼痛装置のFDA認可要件
  • ドラッグデリバリーシステム

第5章 疼痛治療

  • 概要
  • 医薬品による疼痛管理
  • OTC疼痛管理薬:概要
  • 疼痛管理装置
  • 疼痛管理処置:ステロイド、内視鏡、蛍光透視法
  • 疼痛管理の代替手法
  • 補助的・代替疼痛管理手段開発の追跡調査
  • 疼痛管理サービス・組織

第6章 処方疼痛管理市場規模と分析

  • 総市場
  • 処方疼痛薬市場:製品タイプ別
  • 麻薬性鎮痛薬
  • 非麻薬性鎮痛薬
  • 抗片頭痛薬
  • 麻酔薬
  • その他の薬剤クラス
  • 市場参入企業
  • 将来市場分析

第7章 疼痛管理装置市場規模と分析

  • イントロダクション
  • 総市場
  • 製品別市場
    • 電気療法
    • 脊椎刺激装置
    • その他の装置
    • 市場参入企業
    • 将来市場分析

第8章 総市場サマリー

  • 総市場
  • 製品別市場
  • 地域別市場

第9章 業界の発展

  • 近年のイベント・開発のタイムライン
    • 医薬品パイプライン
  • 特許分析
    • 疼痛関連の発行特許数
    • 主な治療の薬剤特許
    • ジェネリック企業のインパクト
    • 疼痛装置の臨床試験
    • 疼痛研究の将来
    • 疼痛研究:小児人口
    • 患者転帰調査
    • 主な疼痛関連の買収・アライアンス

第10章 企業プロファイル

  • 疼痛管理薬・装置メーカー
    • ABBVIE INC.
    • ASTRAZENECA
    • DEPOMED INC.
    • DJO GLOBAL INC.
    • ELI LILLY & CO.
    • ENDO INTERNATIONAL
    • GLAXOSMITHKLINE
    • 久光製薬
    • JOHNSON & JOHNSON
    • MEDTRONIC INC.
    • NOVARTIS INTERNATIONAL AG
    • PFIZER
    • PURDUE PHARMACEUTICALS LP
    • ST. JUDE MEDICAL INC.

第11章 付録I:疼痛管理薬メーカー・ディベロッパー

第12章 付録II:州当局・連絡先

第13章 付録III:米国の疼痛学会・団体

第14章 I付録V:世界の団体・組織

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: HLC026E

REPORT HIGHLIGHTS

Market for global pain management pharmaceuticals and devices by revenue at manufacturers' sales levels is projected to grow from $36.6 billion in 2014 to nearly $37.8 billion in 2015 and $44.3 billion in 2020, with a compound annual growth rate (CAGR) of 3.2% between 2015 and 2020.

This report provides:

  • An overview of the global market for pain management drugs, which will address acute vs. chronic pain, treatments, and issues facing healthcare workers.
  • Analyses of global market trends, with data from 2013 and 2014; estimates for 2015, and projections of CAGRs through 2020.
  • Examination of product categories, use of products, and the competitive landscape.
  • Coverage of several significant market trends, including undertreatment issues, professional issues, managed care pain issues, trends in new therapies, product pipelines, generic participation, pain research, drug delivery, and patent expirations.
  • Discussion of new regulatory requirements.
  • Comprehensive company profiles of major players in the industry.

SCOPE AND FORMAT

This BCC Research report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management. The geographical scope of this study is global. This study will address acute versus chronic pain, treatments and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts and competitive analyses.

The report identifies two general segments of pain management:

  • Pharmaceuticals
  • Devices.

Within the pharmaceuticals segment several sub-segments are discussed in detail, including:

  • Narcotic pain management.
  • Non-narcotic pain management.
  • Antimigraine treatments.
  • Anesthetics.
  • Other drugs (including fibromyalgia treatments).

The device segment covers several product lines and specifically targets the largest product segments including:

  • Electrotherapy stimulators.
  • Spine stimulators.
  • Other products (including electromagnetic therapies and other treatments).

For each market segment detailed information is provided based on product categories, product use, forecasts and competitive analyses.

ANALYST'S CREDENTIALS

Melissa Elder is an experienced healthcare market analyst, specializing in prescription and over-the-counter pharmaceuticals, medical devices, animal health and emerging healthcare technologies. Ms. Elder has more than 20 years of experience in the healthcare industry, specializing in market research for the past 16 years. This experience has given her substantial insight into pharmaceutical and medical device market analysis. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare markets.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY AND INTENDED AUDIENCE
  • SCOPE AND FORMAT
  • METHODOLOGY AND SOURCES OF INFORMATION
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • OVERVIEW
  • GENERAL PAIN TERMINOLOGY
  • MAJOR MARKETS SUMMARY
    • SUMMARY TABLE: MARKET FOR GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, THROUGH 2020 ($ MILLIONS)
    • SUMMARY FIGURE: MARKET FOR GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, 2012-2020 ($ MILLIONS)
  • MARKET TRENDS
    • UNDERTREATMENT ISSUES
    • PROFESSIONAL PAIN TREATMENT ISSUES
    • ACCESS TO CARE
    • FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES
    • DRUG DELIVERY SYSTEMS

CHAPTER 3 - INDUSTRY OVERVIEW

  • HISTORY OF PAIN AND PAIN TREATMENT
    • THE PERCEPTION OF PAIN
      • Types of Pain
        • Acute Pain
        • Chronic Pain
    • ASSESSMENT OF PAIN
      • Subjective
      • Objective
        • TABLE 1: OBJECTIVE SIGNS OF PAIN
  • HOW PAIN IS DIAGNOSED
  • HOW PAIN IS TREATED
    • FIGURE 1: PAIN-MANAGEMENT TECHNIQUES
  • DEMOGRAPHICS AND AGING POPULATIONS
    • Global Demographic Overview
      • TABLE 2: GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
      • FIGURE 2: GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)
    • The Aging Population
      • TABLE 3: ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
      • FIGURE 3: ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)
    • Global Life Expectancy
      • TABLE 4: GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2015 (YEARS)
      • FIGURE 4: GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2015 (YEARS)
  • THE NEED FOR PAIN MANAGEMENT
    • Developments in Treating Neuropathic Pain
  • MIGRAINE HEADACHE PAIN MANAGEMENT
    • CANCER PAIN MANAGEMENT
      • Pain Management in Cancer
        • FIGURE 5: CAUSES OF CANCER PAIN
        • TABLE 5: CANCER PAIN MEDICATIONS
      • Developments in Breakthrough Cancer Pain
    • ORTHOPEDIC PAIN MANAGEMENT
      • Osteoarthritis
      • Rheumatoid Arthritis
      • Ankylosing Spondylitis
      • Fibromyalgia
      • Gout
      • Scleroderma
      • Lupus
      • Bursitis and Tendonitis
        • TABLE 6: ESTIMATED* PREVALENCE/INCIDENCE OF ORTHOPEDIC CONDITIONS BY COUNTRY, AVERAGE FIGURE, 2010-2013 (MILLIONS)
        • FIGURE 6: ESTIMATED* PREVALENCE/INCIDENCE OF ORTHOPEDIC CONDITIONS BY COUNTRY, AVERAGE FIGURE 2010-2013 (MILLIONS)
  • HIV/AIDS RELATED PAIN
    • BURN PAIN
      • Stages of Burn Healing
      • Challenges Associated with Burn Pain
      • Burn Pain Management
        • FIGURE 7: APPROACH TO BURN PAIN MANAGEMENT
    • DENTAL PAIN
      • Treatment for Dental Pain
    • OBSTETRICS PAIN
      • TABLE 7: BIRTH RATES AND BIRTHS BY COUNTRY, 2015 (THOUSANDS)
      • FIGURE 8: BIRTH RATES AND BIRTHS BY COUNTRY, 2015 (THOUSANDS)
  • SURGICAL PAIN
    • GENDER AND PAIN
      • TABLE 8: PEOPLE WHO REPORTED PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*, 1997-2010 (THOUSANDS)
    • OTHER INFLUENCES DETERMINING HOW PAIN IS FELT AMONG INDIVIDUALS
      • Objective Pain Measurement
  • PEDIATRIC PAIN

CHAPTER 4 - INDUSTRY TRENDS

  • OVERVIEW
  • UNDERTREATMENT ISSUES
    • PAIN IN OLDER PATIENTS
    • PAIN IN YOUNGER PATIENTS
  • TREATMENT OF PAIN AND ISSUES FACING THE PROFESSIONAL SEGMENT
    • TABLE 9: AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECT REGION/COUNTRY
  • PRESCRIPTION DRUG MONITORING PROGRAMS
    • TABLE 10: NUMBER OF AGENCIES RESPONSIBLE FOR PDMP IN EACH STATE, BY TYPE
    • TABLE 11: BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDS
    • TABLE 12: DRUGS MONITORED BY PDMPS
    • TABLE 13: STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS
    • FIGURE 9: NUMBER OF STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS BY YEAR OF ENACTMENT
    • TABLE 14: NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT BY REQUIRING STATE
  • ACCESS TO CARE
    • ACCESS TO PALLIATIVE CARE
      • Assessing the Need for Palliative Care
        • FIGURE 10: NUMBER OF DEATHS, BY CAUSES OF MORTALITY AND POTENTIAL NEED FOR PALLIATIVE CARE (MILLIONS)
    • AVAILABILITY OF MEDICATIONS
      • TABLE 15: WHO ESSENTIAL MEDICINES LIST (ADULTS) FOR PAIN MANAGEMENT
      • TABLE 16: AVAILABILITY OF INJECTABLE MORPHINE BY REGION
      • TABLE 17: AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS, BY REGION
      • International Narcotics Control Board and Obstacles to Availability
        • FIGURE 11: FACTORS AFFECTING AVAILABILITY OF OPIOIDS FOR MEDICAL NEEDS, 2010
    • GOVERNMENT INTERVENTION
      • Drug Supply
      • FDA Drug Shortages for Pain Therapies
        • TABLE 18: FDA ANALGESIA DRUG SHORTAGES BY REPORTING COMPANY, JULY 2015
      • Single Convention on Narcotic Drugs
      • Government Subsidies
  • PREVENTING OPIOID-INDUCED CONSTIPATION AND REDUCED COMPLIANCE
    • PUBLIC HEALTHCARE SYSTEMS AROUND THE WORLD
      • TABLE 19: WORLD HEALTH ORGANIZATION TOP 50 RANKING OF HEALTHCARE SYSTEMS, 2000
    • RISING HEALTHCARE COSTS
      • TABLE 20: HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980-2015 (%)
      • FIGURE 12: HEALTH EXPENDITURES AS PERCENT OF GDP BY COUNTRY, 1980-2015 (%)
    • AVERAGE LENGTH OF STAY
  • MANAGED CARE PAIN MANAGEMENT ISSUES
  • FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES
  • FDA APPROVAL REQUIREMENTS FOR PAIN DEVICES
    • 510(K) EXEMPTIONS
      • TABLE 21: PARTS 862-892 OF 21 CFR
    • RISK EVALUATION AND MITIGATION STRATEGY (REMS)
      • TABLE 22: LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID BRAND-NAME PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, MAY 2015
      • TABLE 23: LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID GENERIC PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, MAY 2015
      • TABLE 24: TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTS REQUIRED TO HAVE TIRF REMS ACCESS PROGRAM
    • ACETAMINOPHEN AND FDA CHANGES
      • TABLE 25: MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTION PRODUCTS
    • CODEINE IN COUGH AND COLD MEDICATIONS
      • NON-ASPIRIN NSAIDS LINKED TO INCREASED RISK OF HEART ATTACK OR STROKE
        • TABLE 26: NON-ASPIRIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
  • DRUG DELIVERY SYSTEMS
    • ORAL AND EXTENDED RELEASE
    • TOPICAL AND TRANSDERMAL
    • INTRAVENOUS
    • INTRANASAL
    • PATIENT-CONTROLLED ANALGESIA
    • IONTOPHORESIS
      • TABLE 27: ADVANTAGES AND DISADVANTAGES OF IONTOPHORETIC DRUG DELIVERY
    • ELECTROMECHANICAL TRANSPORT

CHAPTER 5 - TREATING PAIN

  • OVERVIEW
  • PHARMACEUTICAL PAIN MANAGEMENT
    • PRESCRIPTION PAIN MANAGEMENT PRODUCTS
      • TABLE 28: RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-JULY 2015
      • Analgesic Drugs
        • Non-Narcotics
        • Narcotics
          • Full and Partial Agonists
          • Agonist-Antagonists
      • Nonsteroid Anti-inflammatory Drugs
      • Antimigraine Drugs
      • Antidepressant, Anticonvulsants and Other Pain Relieving Drugs
      • Anesthetics
        • General Anesthesia
          • TABLE 29: MOST COMMONLY USED GENERAL ANESTHETIC AGENTS
        • Local/Regional
        • Topical
  • OVER-THE-COUNTER PAIN MANAGEMENT PRODUCTS: OVERVIEW
    • ANALGESIC DRUGS
      • TABLE 30: OTC ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION PRODUCTS
    • NONSTEROID ANTI-INFLAMMATORY DRUGS
      • Aspirin Products and Aspirin Combination Products
        • TABLE 31: OTC ASPIRIN AND ASPIRIN COMBINATION PRODUCTS
      • Ibuprofen and Ibuprofen Combination Products
        • TABLE 32: OTC IBUPROFEN AND IBUPROFEN COMBINATION PRODUCTS
      • Ketoprofen Products
        • TABLE 33: OTC KETOPROFEN PRODUCTS
      • Naproxen Compounds
        • TABLE 34: OTC NONSTEROID ANTI-INFLAMMATORIES
    • ANTIMIGRAINE DRUGS
      • TABLE 35: OTC ANTIMIGRAINE PRODUCTS
    • TOPICAL ANESTHETIC DRUGS
      • TABLE 36: OTC TOPICAL ANESTHETIC PRODUCTS
  • PAIN MANAGEMENT DEVICES
    • STIMULATION THERAPY
      • Electrotherapy
      • Neuromuscular Stimulators
      • Pain TEM
      • Spine Stimulation
    • COMBINATION PAIN MANAGEMENT DEVICES
    • LASER DEVICES
    • ELECTROMAGNETIC THERAPY DEVICES
    • INTRATHECAL DEVICES
    • OTHER PAIN DEVICES AND METHODS
  • PAIN MANAGEMENT PROCEDURES: STEROIDS, ENDOSCOPY AND FLUOROSCOPY
  • ALTERNATIVE METHODS OF PAIN MANAGEMENT
    • PHYSICAL PAIN TREATMENT MODALITIES
      • Acupuncture/Acupressure
      • Ice (Cryotherapy)
      • Joint Mobilization
      • Manipulation
      • Massage
      • Traction
      • Radiation Therapy
      • Radio Frequency Neuroablation, Epiduroscopy
      • Surgery
      • Whirlpool Bath (Thermotherapy)
    • PSYCHOLOGICAL PAIN THERAPIES
      • Biofeedback
      • Hypnosis
      • Behavior Modification/Operant Conditioning
      • Relaxation and Stress Management Training
      • Imagery
      • Autogenic Training
      • Psychosocial Interventions
      • Distraction and Reframing
  • TRACKING THE DEVELOPMENT OF COMPLEMENTARY AND ALTERNATIVE PAIN CONTROL METHODS
    • TABLE 37: ADULTS 18 YEARS AND OVER IN THE U.S. WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY THERAPY TYPE, 2002-2015 (THOUSANDS)
    • FIGURE 13: ADULTS 18 YEARS AND OVER IN THE U.S. WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY THERAPY TYPE, 2002-2015 (THOUSANDS)
  • PAIN MANAGEMENT SERVICES AND ORGANIZATIONS
    • HOME CARE
    • HOSPICE
      • FIGURE 14: NUMBER OF HOSPICE PATIENTS SERVED BY YEAR, 2009--2013
      • TABLE 38: STATISTICS FOR HOSPICE PATIENTS BY CHARACTERISTIC, 2009-2013 (%)
      • FIGURE 15: PERCENTAGE OF HOSPICE PATIENTS BY GENDER, 2009-2013 (%)
      • FIGURE 16: PERCENTAGE OF HOSPICE PATIENTS BY AGE GROUP, 2009-2013 (%)
      • TABLE 39: STATISTICS OF HOSPICE PATIENTS BY PRIMARY DIAGNOSIS (THOUSAND/%)
      • FIGURE 17: PERCENTAGE OF HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009-2013 (%)
    • NATIONAL HOSPICE AND PALLIATIVE CARE ORGANIZATION
      • TABLE 40: NHPCO COMMITTEES
    • HOSPITALS
      • TABLE 41: NUMBER OF REGISTERED HOSPITALS BY COUNTRY, 2010
      • TABLE 42: NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2013
      • Hospital Departments
        • Emergency Rooms
        • Critical Care Units
    • PAIN CLINICS
      • TABLE 43: NUMBER OF REGISTERED PAIN CLINICS IN THE U.S. BY STATE, 2015
      • TABLE 44: NUMBER OF REGISTERED PAIN CLINICS, BY COUNTRY
    • SKILLED NURSING FACILITIES

CHAPTER 6 - PHARMACEUTICAL PAIN MANAGEMENT MARKET SIZE AND ANALYSIS

  • TOTAL MARKET
  • PRESCRIPTION PAIN MARKETS BY PRODUCT TYPE
    • TABLE 45: MARKET FOR GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS AT MANUFACTURERS' SALES LEVELS BY CATEGORY, THROUGH 2020 ($ MILLIONS)
    • FIGURE 18: MARKET FOR GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS AT MANUFACTURERS' SALES LEVELS BY CATEGORY, 2012-2020 ($ MILLIONS)
  • NARCOTIC ANALGESICS
    • TABLE 46: GLOBAL MARKET FOR NARCOTIC ANALGESICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 19: GLOBAL MARKET FOR NARCOTIC ANALGESICS BY REGION, 2012-2020 ($ MILLIONS)
  • NON-NARCOTIC ANALGESICS
    • TABLE 47: GLOBAL MARKET FOR NON-NARCOTIC ANALGESICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 20: GLOBAL MARKET FOR NON-NARCOTIC ANALGESICS BY REGION, 2012-2020 ($ MILLIONS)
  • ANTIMIGRAINE AGENTS
    • TABLE 48: GLOBAL MARKET FOR ANTIMIGRAINE AGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 21: GLOBAL MARKET FOR ANTIMIGRAINE AGENTS BY REGION, 2012-2020 ($ MILLIONS)
  • ANESTHETICS
    • TABLE 49: GLOBAL MARKET FOR ANESTHETICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 22: GLOBAL MARKET FOR ANESTHETICS BY REGION, 2012-2020 ($ MILLIONS)
  • OTHER DRUG CLASSES
    • TABLE 50: GLOBAL MARKET FOR OTHER CNS ANALGESICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 23: GLOBAL MARKET FOR OTHER CNS ANALGESICS BY REGION, 2012-2020 ($ MILLIONS)
  • MARKET PARTICIPANTS
    • NARCOTIC/NON-NARCOTIC MARKET SHARE
      • TABLE 51: GLOBAL MARKET FOR PRESCRIPTION NARCOTIC AND NON-NARCOTIC BY MANUFACTURER, 2015 ($ MILLIONS/%)
      • FIGURE 24: GLOBAL MARKET FOR PRESCRIPTION NARCOTIC AND NON-NARCOTIC BY MANUFACTURER, 2015 ($ MILLIONS)
    • MIGRAINE TREATMENT MARKET SHARE
      • TABLE 52: GLOBAL MARKET FOR PRESCRIPTION ANTIMIGRAINE DRUG BY MANUFACTURER, 2015 ($ MILLIONS/%)
      • FIGURE 25: GLOBAL MARKET FOR PRESCRIPTION ANTIMIGRAINE DRUG BY MANUFACTURER, 2015 (%)
    • ANESTHETIC MARKET SHARE
      • TABLE 53: GLOBAL MARKET FOR PRESCRIPTION ANESTHETIC BY MANUFACTURER, 2015 ($ MILLIONS/%)
      • FIGURE 26: GLOBAL MARKET FOR PRESCRIPTION ANESTHETIC BY MANUFACTURER, 2015 (%)
    • FUTURE MARKET ANALYSIS

CHAPTER 7 - PAIN MANAGEMENT DEVICE MARKET SIZE AND ANALYSIS

  • INTRODUCTION
  • TOTAL PAIN MANAGEMENT DEVICE MARKET
    • FIGURE 27: GLOBAL PAIN MANAGEMENT DEVICE MARKET AT MANUFACTURERS' SALES LEVELS, 2012-2020 ($ MILLIONS)
  • PAIN MARKETS BY PRODUCT TYPE
    • ELECTROTHERAPY
    • SPINE STIMULATORS
    • OTHER PAIN TREATMENT DEVICES
      • TABLE 54: GLOBAL PAIN MANAGEMENT DEVICE MARKET AT MANUFACTURERS' SALES LEVELS BY PRODUCT TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 28: GLOBAL PAIN MANAGEMENT DEVICE MARKET BY PRODUCT TYPE, 2012-2020 ($ MILLIONS)
      • TABLE 55: GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, THROUGH 2020 ($ MILLIONS)
      • FIGURE 29: GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, 2012-2020 ($ MILLIONS)
    • MARKET PARTICIPANTS
      • TABLE 56: GLOBAL MARKET FOR NEUROMUSCULAR STIMULATOR/ELECTROTHERAPY DEVICES BY MANUFACTURER, 2015 ($ MILLIONS/%)
      • FIGURE 30: GLOBAL MARKET SHARE FOR NEUROMUSCULAR STIMULATOR/ELECTROTHERAPY DEVICES BY MANUFACTURER, 2015 (%)
      • TABLE 57: GLOBAL MARKET FOR SPINE STIMULATORS BY MANUFACTURER, 2015 ($ MILLIONS/%)
      • FIGURE 31: GLOBAL MARKET SHARE FOR SPINE CORD STIMULATORS BY MANUFACTURER, 2015 (%)
    • FUTURE MARKET ANALYSIS

CHAPTER 8 - TOTAL MARKET SUMMARY

  • TOTAL PAIN MANAGEMENT MARKET
    • TABLE 58: GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, THROUGH 2020 ($ MILLIONS)
    • FIGURE 32: GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, 2012-2020 ($ MILLIONS)
  • MARKET PERCENTAGE BY PRODUCT TYPE
    • TABLE 59: GLOBAL PAIN MANAGEMENT MARKET BY SEGMENT, 2015 ($ MILLIONS/%)
    • FIGURE 33: GLOBAL PAIN MANAGEMENT MARKET SHARE BY SEGMENT, 2015 (%)
  • MARKETS BY GLOBAL REGION
    • TABLE 60: GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 34: GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, 2012-2020 ($ MILLIONS)

CHAPTER 9 - INDUSTRY DEVELOPMENTS

  • TIMELINE OF RECENT EVENTS AND DEVELOPMENTS
    • THE PHARMACEUTICAL PIPELINE
      • TABLE 61: MANUFACTURERS' PAIN-MANAGEMENT DRUG PIPELINES
      • FIGURE 35: PAIN MANAGEMENT DRUG PIPELINE, BY DEVELOPMENT STATUS
      • FIGURE 36: PAIN MANAGEMENT DRUG PIPELINE, BY PRIMARY INDICATION
  • PATENT ANALYSIS
    • NUMBER OF PATENTS ISSUED FOR PAIN
      • TABLE 62: NUMBER OF PAIN FOCUS PATENTS ISSUED, BY ABSTRACT DESCRIPTION
      • TABLE 63: NUMBER OF U.S. PATENTS FOR PAIN-FOCUSED INVENTIONS BY YEAR, JANUARY 2000-JULY 2015
      • FIGURE 37: NUMBER OF U.S. PATENTS FOR PAIN-FOCUSED INVENTIONS BY YEAR, JANUARY 2000-JULY 2015
    • DRUG PATENTS FOR SELECTED THERAPIES
      • TABLE 64: U.S. PATENT EXPIRATION DATES FOR SELECTED PAIN DRUGS
    • IMPACT OF GENERIC PARTICIPATION
      • TABLE 65: FIRST-TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS, APRIL 2005-JULY 2015
    • PAIN DEVICE CLINICAL TRIALS
      • TABLE 66: SELECTED PAIN MANAGEMENT DEVICE TRIALS
      • FIGURE 38: NUMBER OF PAIN MANAGEMENT DEVICES IN DEVELOPMENT, BY GENERAL STATUS
    • FUTURE OF PAIN RESEARCH
      • TABLE 67: PAIN OR PAIN-RELATED CLINICAL TRIALS, BY REGION, 2015
      • FIGURE 39: PERCENTAGE OF PAIN-FOCUSED CLINICAL TRIALS FOR ALL AGES, BY REGION (%)
    • PAIN RESEARCH - PEDIATRIC POPULATIONS
      • FIGURE 40: PERCENTAGE OF PAIN-FOCUSED CLINICAL TRIALS FOR PEDIATRICS, BY REGION (%)
    • PATIENT OUTCOMES RESEARCH
    • SELECTED PAIN-RELATED ACQUISITIONS AND ALLIANCES

CHAPTER 10 - COMPANY PROFILES

  • PHARMACEUTICAL AND DEVICE PAIN MANAGEMENT MANUFACTURERS
    • ABBVIE INC.
    • ASTRAZENECA
    • DEPOMED INC.
    • DJO GLOBAL INC.
    • ELI LILLY & CO.
    • ENDO INTERNATIONAL
    • GLAXOSMITHKLINE
    • HISAMITSU PHARMACEUTICAL CO. INC.
    • JOHNSON & JOHNSON
    • MEDTRONIC INC.
    • NOVARTIS INTERNATIONAL AG
    • PFIZER
    • PURDUE PHARMACEUTICALS LP
    • ST. JUDE MEDICAL INC.

CHAPTER 11 - APPENDIX I

  • PAIN MANAGEMENT PHARMACEUTICAL MANUFACTURERS AND DEVELOPERS

CHAPTER 12 - APPENDIX II

  • 2015-2016 STATE CONTROLLED SUBSTANCES SCHEDULING AUTHORITIES AND OTHER HELPFUL CONTACT PERSONS
    • ALABAMA
    • ALASKA
    • ARIZONA
    • ARKANSAS
    • CALIFORNIA
    • COLORADO
    • CONNECTICUT
    • DELAWARE
    • DISTRICT OF COLUMBIA
    • FLORIDA
    • GEORGIA
    • HAWAII
    • IDAHO
    • ILLINOIS
    • INDIANA
    • IOWA
    • KANSAS
    • KENTUCKY
    • LOUISIANA
    • MAINE
    • MARYLAND
    • MASSACHUSETTS
    • MICHIGAN
    • MINNESOTA
    • MISSISSIPPI
    • MISSOURI
    • MONTANA
    • NEBRASKA
    • NEVADA
    • NEW HAMPSHIRE
    • NEW JERSEY
    • NEW MEXICO
    • NEW YORK
    • NORTH CAROLINA
    • NORTH DAKOTA
    • OHIO
    • OKLAHOMA
    • OREGON
    • PENNSYLVANIA
    • RHODE ISLAND
    • SOUTH CAROLINA
    • SOUTH DAKOTA
    • TENNESSEE
    • TEXAS
    • UTAH
    • VERMONT
    • VIRGINIA
    • WASHINGTON
    • WEST VIRGINIA
    • WISCONSIN
    • WYOMING

CHAPTER 13 - APPENDIX III

  • U.S. PAIN SOCIETIES AND ASSOCIATIONS

CHAPTER 14 - APPENDIX IV

  • INTERNATIONAL ASSOCIATIONS AND ORGANIZATIONS

LIST OF TABLES

  • SUMMARY TABLE: MARKET FOR GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: OBJECTIVE SIGNS OF PAIN
    • TABLE 2: GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
    • TABLE 3: ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
    • TABLE 4: GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2015 (YEARS)
    • TABLE 5: CANCER PAIN MEDICATIONS
    • TABLE 6: ESTIMATED* PREVALENCE/INCIDENCE OF ORTHOPEDIC CONDITIONS BY COUNTRY, AVERAGE FIGURE, 2010-2013 (MILLIONS)
    • TABLE 7: BIRTH RATES AND BIRTHS BY COUNTRY, 2015 (THOUSANDS)
    • TABLE 8: PEOPLE WHO REPORTED PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION*, 1997-2010 (THOUSANDS)
    • TABLE 9: AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECT REGION/COUNTRY
    • TABLE 10: NUMBER OF AGENCIES RESPONSIBLE FOR PDMP IN EACH STATE, BY TYPE
    • TABLE 11: BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDS
    • TABLE 12: DRUGS MONITORED BY PDMPS
    • TABLE 13: STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS
    • TABLE 14: NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT BY REQUIRING STATE
    • TABLE 15: WHO ESSENTIAL MEDICINES LIST (ADULTS) FOR PAIN MANAGEMENT
    • TABLE 16: AVAILABILITY OF INJECTABLE MORPHINE BY REGION
    • TABLE 17: AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS, BY REGION
    • TABLE 18: FDA ANALGESIA DRUG SHORTAGES BY REPORTING COMPANY, JULY 2015
    • TABLE 19: WORLD HEALTH ORGANIZATION TOP 50 RANKING OF HEALTHCARE SYSTEMS, 2000
    • TABLE 20: HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980-2015 (%)
    • TABLE 21: PARTS 862-892 OF 21 CFR
    • TABLE 22: LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID BRAND-NAME PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, MAY 2015
    • TABLE 23: LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID GENERIC PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, MAY 2015
    • TABLE 24: TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTS REQUIRED TO HAVE TIRF REMS ACCESS PROGRAM
    • TABLE 25: MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTION PRODUCTS
    • TABLE 26: NON-ASPIRIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
    • TABLE 27: ADVANTAGES AND DISADVANTAGES OF IONTOPHORETIC DRUG DELIVERY
    • TABLE 28: RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-JULY 2015
    • TABLE 29: MOST COMMONLY USED GENERAL ANESTHETIC AGENTS
    • TABLE 30: OTC ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION PRODUCTS
    • TABLE 31: OTC ASPIRIN AND ASPIRIN COMBINATION PRODUCTS
    • TABLE 32: OTC IBUPROFEN AND IBUPROFEN COMBINATION PRODUCTS
    • TABLE 33: OTC KETOPROFEN PRODUCTS
    • TABLE 34: OTC NONSTEROID ANTI-INFLAMMATORIES
    • TABLE 35: OTC ANTIMIGRAINE PRODUCTS
    • TABLE 36: OTC TOPICAL ANESTHETIC PRODUCTS
    • TABLE 37: ADULTS 18 YEARS AND OVER IN THE U.S. WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY THERAPY TYPE, 2002-2015 (THOUSANDS)
    • TABLE 38: STATISTICS FOR HOSPICE PATIENTS BY CHARACTERISTIC, 2009-2013 (%)
    • TABLE 39: STATISTICS OF HOSPICE PATIENTS BY PRIMARY DIAGNOSIS (THOUSAND/%)
    • TABLE 40: NHPCO COMMITTEES
    • TABLE 41: NUMBER OF REGISTERED HOSPITALS BY COUNTRY, 2010
    • TABLE 42: NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2013
    • TABLE 43: NUMBER OF REGISTERED PAIN CLINICS IN THE U.S. BY STATE, 2015
    • TABLE 44: NUMBER OF REGISTERED PAIN CLINICS, BY COUNTRY
    • TABLE 45: MARKET FOR GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS AT MANUFACTURERS' SALES LEVELS BY CATEGORY, THROUGH 2020 ($ MILLIONS)
    • TABLE 46: GLOBAL MARKET FOR NARCOTIC ANALGESICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 47: GLOBAL MARKET FOR NON-NARCOTIC ANALGESICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 48: GLOBAL MARKET FOR ANTIMIGRAINE AGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 49: GLOBAL MARKET FOR ANESTHETICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 50: GLOBAL MARKET FOR OTHER CNS ANALGESICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 51: GLOBAL MARKET FOR PRESCRIPTION NARCOTIC AND NON-NARCOTIC BY MANUFACTURER, 2015 ($ MILLIONS/%)
    • TABLE 52: GLOBAL MARKET FOR PRESCRIPTION ANTIMIGRAINE DRUG BY MANUFACTURER, 2015 ($ MILLIONS/%)
    • TABLE 53: GLOBAL MARKET FOR PRESCRIPTION ANESTHETIC BY MANUFACTURER, 2015 ($ MILLIONS/%)
    • TABLE 54: GLOBAL PAIN MANAGEMENT DEVICE MARKET AT MANUFACTURERS' SALES LEVELS BY PRODUCT TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 55: GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 56: GLOBAL MARKET FOR NEUROMUSCULAR STIMULATOR/ELECTROTHERAPY DEVICES BY MANUFACTURER, 2015 ($ MILLIONS/%)
    • TABLE 57: GLOBAL MARKET FOR SPINE STIMULATORS BY MANUFACTURER, 2015 ($ MILLIONS/%)
    • TABLE 58: GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, THROUGH 2020 ($ MILLIONS)
    • TABLE 59: GLOBAL PAIN MANAGEMENT MARKET BY SEGMENT, 2015 ($ MILLIONS/%)
    • TABLE 60: GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 61: MANUFACTURERS' PAIN-MANAGEMENT DRUG PIPELINES
    • TABLE 62: NUMBER OF PAIN FOCUS PATENTS ISSUED, BY ABSTRACT DESCRIPTION
    • TABLE 63: NUMBER OF U.S. PATENTS FOR PAIN-FOCUSED INVENTIONS BY YEAR, JANUARY 2000-JULY 2015
    • TABLE 64: U.S. PATENT EXPIRATION DATES FOR SELECTED PAIN DRUGS
    • TABLE 65: FIRST-TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS, APRIL 2005-JULY 2015
    • TABLE 66: SELECTED PAIN MANAGEMENT DEVICE TRIALS
    • TABLE 67: PAIN OR PAIN-RELATED CLINICAL TRIALS, BY REGION, 2015

LIST OF FIGURES

  • SUMMARY FIGURE: MARKET FOR GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, 2012-2020 ($ MILLIONS)
    • FIGURE 1: PAIN-MANAGEMENT TECHNIQUES
    • FIGURE 2: GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)
    • FIGURE 3: ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)
    • FIGURE 4: GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2015 (YEARS)
    • FIGURE 5: CAUSES OF CANCER PAIN
    • FIGURE 6: ESTIMATED* PREVALENCE/INCIDENCE OF ORTHOPEDIC CONDITIONS BY COUNTRY, AVERAGE
    • FIGURE 2: 10-2013 (MILLIONS)
    • FIGURE 7: APPROACH TO BURN PAIN MANAGEMENT
    • FIGURE 8: BIRTH RATES AND BIRTHS BY COUNTRY, 2015 (THOUSANDS)
    • FIGURE 9 : UMBER OF STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS BY YEAR OF ENACTMENT
    • FIGURE 10: NUMBER OF DEATHS, BY CAUSES OF MORTALITY AND POTENTIAL NEED FOR PALLIATIVE CARE (MILLIONS)
    • FIGURE 11: FACTORS AFFECTING AVAILABILITY OF OPIOIDS FOR MEDICAL NEEDS, 2010
    • FIGURE 12: HEALTH EXPENDITURES AS PERCENT OF GDP BY COUNTRY, 1980-2015 (%)
    • FIGURE 13: ADULTS 18 YEARS AND OVER IN THE U.S. WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY THERAPY TYPE, 2002-2015 (THOUSANDS)
    • FIGURE 14: NUMBER OF HOSPICE PATIENTS SERVED BY YEAR, 2009--2013
    • FIGURE 15: PERCENTAGE OF HOSPICE PATIENTS BY GENDER, 2009-2013 (%)
    • FIGURE 16: PERCENTAGE OF HOSPICE PATIENTS BY AGE GROUP, 2009-2013 (%)
    • FIGURE 17: PERCENTAGE OF HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009-2013 (%)
    • FIGURE 18: MARKET FOR GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS AT MANUFACTURERS' SALES LEVELS BY CATEGORY, 2012-2020 ($ MILLIONS)
    • FIGURE 19: GLOBAL MARKET FOR NARCOTIC ANALGESICS BY REGION, 2012-2020 ($ MILLIONS)
    • FIGURE 20: GLOBAL MARKET FOR NON-NARCOTIC ANALGESICS BY REGION, 2012-2020 ($ MILLIONS)
    • FIGURE 21: GLOBAL MARKET FOR ANTIMIGRAINE AGENTS BY REGION, 2012-2020 ($ MILLIONS)
    • FIGURE 22: GLOBAL MARKET FOR ANESTHETICS BY REGION, 2012-2020 ($ MILLIONS)
    • FIGURE 23: GLOBAL MARKET FOR OTHER CNS ANALGESICS BY REGION, 2012-2020 ($ MILLIONS)
    • FIGURE 24: GLOBAL MARKET FOR PRESCRIPTION NARCOTIC AND NON-NARCOTIC BY MANUFACTURER, 2015 ($ MILLIONS)
    • FIGURE 25: GLOBAL MARKET FOR PRESCRIPTION ANTIMIGRAINE DRUG BY MANUFACTURER, 2015 (%)
    • FIGURE 26: GLOBAL MARKET FOR PRESCRIPTION ANESTHETIC BY MANUFACTURER, 2015 (%)
    • FIGURE 27: GLOBAL PAIN MANAGEMENT DEVICE MARKET AT MANUFACTURERS' SALES LEVELS, 2012-2020 ($ MILLIONS)
    • FIGURE 28: GLOBAL PAIN MANAGEMENT DEVICE MARKET BY PRODUCT TYPE, 2012-2020 ($ MILLIONS)
    • FIGURE 29: GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, 2012-2020 ($ MILLIONS)
    • FIGURE 30: GLOBAL MARKET SHARE FOR NEUROMUSCULAR STIMULATOR/ELECTROTHERAPY DEVICES BY MANUFACTURER, 2015 (%)
    • FIGURE 31: GLOBAL MARKET SHARE FOR SPINE CORD STIMULATORS BY MANUFACTURER, 2015 (%)
    • FIGURE 32: GLOBAL MARKET FOR PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES BY REVENUE AT MANUFACTURERS' SALES LEVELS, 2012-2020 ($ MILLIONS)
    • FIGURE 33: GLOBAL PAIN MANAGEMENT MARKET SHARE BY SEGMENT, 2015 (%)
    • FIGURE 34: GLOBAL MARKET FOR PAIN MANAGEMENT DEVICES BY REGION, 2012-2020 ($ MILLIONS)
    • FIGURE 35: PAIN MANAGEMENT DRUG PIPELINE, BY DEVELOPMENT STATUS
    • FIGURE 36: PAIN MANAGEMENT DRUG PIPELINE, BY PRIMARY INDICATION
    • FIGURE 37: NUMBER OF U.S. PATENTS FOR PAIN-FOCUSED INVENTIONS BY YEAR, JANUARY 2000-JULY 2015
    • FIGURE 38: NUMBER OF PAIN MANAGEMENT DEVICES IN DEVELOPMENT, BY GENERAL STATUS
    • FIGURE 39: PERCENTAGE OF PAIN-FOCUSED CLINICAL TRIALS FOR ALL AGES, BY REGION (%)
    • FIGURE 40: PERCENTAGE OF PAIN-FOCUSED CLINICAL TRIALS FOR PEDIATRICS, BY REGION (%)
Back to Top